Literature DB >> 6976848

Studies on the pharmacokinetics of primaquine.

K A Fletcher, D A Evans, H M Gilles, J Greaves, D Bunnag, T Harinasuta.   

Abstract

A sensitive and specific assay for primaquine in plasma and urine using gas chromatography/mass spectrometry has been developed and used to study the plasma kinetics of primaquine. Preliminary studies on the effects of single and multiple oral doses have been carried out. In both cases the drug was completely, or almost completely, removed from the plasma in 24 h. The concentration of primaquine in the plasma usually reached a peak 1-2 hours after oral administration. The plasma elimination half-life was about 4 h. Less than 1% of the dose was detected in the urine collected over a 24-h period following drug ingestion. When Caucasian volunteers were given primaquine and chloroquine concurrently, some of them developed significant methaemoglobinaemia. Primaquine was not detectable in the plasma of any of the volunteers, 24 h after each daily dose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976848      PMCID: PMC2396059     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  7 in total

1.  Studies on metabolic degradation of pamaquin (plasmoquin) in monkeys.

Authors:  H L BAMI; M S DHATT; G S AHLUWALIA; A P RAY
Journal:  Indian J Malariol       Date:  1960-03

2.  Metabolism of pentaquine in the rhesus monkey.

Authors:  C C SMITH
Journal:  J Pharmacol Exp Ther       Date:  1956-01       Impact factor: 4.030

3.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VIII. THE PHYSIOLOGICAL DISPOSITION OF PAMAQUINE.

Authors:  C G Zubrod; T J Kennedy; J A Shannon
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

4.  Urinary primaquine excretion and red cell methaemoglobin levels in man following a primaquine:chloroquine regimen.

Authors:  J Greaves; D A Evans; K A Fletcher
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

5.  The metabolism of chloroquine in man during and after repeated oral dosage.

Authors:  E W McChesney; M J Fasco; W F Banks
Journal:  J Pharmacol Exp Ther       Date:  1967-11       Impact factor: 4.030

6.  A selected ion monitoring assay for primaquine in plasma and urine.

Authors:  J Greaves; D A Price-Evans; H M Gilles; J D Baty
Journal:  Biomed Mass Spectrom       Date:  1979-03

7.  Plasma kinetics and urinary excretion of primaquine in man.

Authors:  J Greaves; D A Evans; H M Gilles; K A Fletcher; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

  7 in total
  17 in total

Review 1.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  The six diseases of WHO. Malaria.

Authors:  H M Gilles
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-21

4.  Doses of primaquine administered to children with Plasmodium vivax according to an age-based dose regimen.

Authors:  Michelle Valeria Dias Ferreira Vieira; Tamyris Regina Matos Lopes; Amanda Gabryelle Nunes Cardoso Mello; Luann Wendel Pereira de Sena; Robert J Commons; José Luiz Fernandes Vieira
Journal:  Pathog Glob Health       Date:  2020-07-24       Impact factor: 2.894

Review 5.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 6.  Treatment of malaria--1990.

Authors:  D M Panisko; J S Keystone
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 7.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

8.  HIV treatments have malaria gametocyte killing and transmission blocking activity.

Authors:  Charlotte V Hobbs; Takeshi Q Tanaka; Olga Muratova; Jillian Van Vliet; William Borkowsky; Kim C Williamson; Patrick E Duffy
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

9.  Pharmacokinetics of primaquine in patients with P. vivax malaria.

Authors:  S C Bhatia; Y S Saraph; S N Revankar; K J Doshi; E D Bharucha; N D Desai; A B Vaidya; D Subrahmanyam; K C Gupta; R S Satoskar
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.

Authors:  Papichaya Phompradit; Poonuch Muhamad; Anurak Cheoymang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2014-06-02       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.